Additionally, in a study on chronic neutrophilic leukemia (CNL) and atypical (BCR-ABL1–negative) CML in patients with CSF3R mutations, CSF3R truncating mutations were found to be sensitive to dasatinib [50] suggesting that the trial of SRC kinase inhibitors is a reasonable approach [51]. The gene discussed is CSF3R; the disease is chronic neutrophilic leukemia.